CMS must account for inclusion of COVID years in 2023 ACO REACH benchmarks to avoid unfairly penalizing REACH ACOs.
This was originally published by the National Association of ACOs (NAACOs).
Highlights:
Comprised of 132 accountable care organizations (ACOs) and caring for 2.1 million beneficiaries, the ACO REACH Model tests new policies around health equity incentives and primary care capitation, among other things. But preliminary analysis from NAACOS member Physicians of Southwest Washington (PSW) and MultiCare Connected Care in Olympia, Washington, calls attention to a looming issue in the model—including that years impacted by the COVID-19 pandemic will create regional variation that could impede ACOs’ success.
Specifically, CMS will factor years affected by the COVID-19 pandemic into REACH ACOs’ financial benchmarks, creating unfair performance standards for ACOs because of data anomalies. The pandemic caused preventive, routine care to be missed in 2020 and delayed elective surgeries, and not all of that care was made up for in 2021. Furthermore, there were dramatic variations in spending across the country due to some regions more quickly lifting stay-at-home orders and deferring elective procedures.
How are ACO REACH benchmarks determined?
The model’s “rate book”, which spells out Medicare fee-for-service spending in each county in the country, is modified from what’s used in Medicare Advantage. CMS uses the rate book to adjust REACH ACOs’ benchmarks for regional spending. The REACH rate book is based on 3 years’ worth of data (2019-2021) and will include 2 pandemic-stricken years for Performance Year 2023. Last year, the rate book was based off Medicare spending between 2017 and 2019 and didn’t have this problem. Conversely, the Medicare Advantage rate book is 5 years (2016-2020), so 2023 only includes one year of pandemic data and the impact of COVID-19 will be mitigated in later years when averaging across 5 years instead of 3 years.
REACH’s benchmarks in 2023 are made up of 60% of the historical spending of the ACO’s assigned patients and 40% regional expenditures, defined by counties from which the ACO draws patients and determined by the rate book
What is happening?
In short, there is large variation in regional trends between the 2022 rate book and the 2023 rate book due the inclusion of 2020 and 2021. For example, an average-risk beneficiary in Maine would receive a 1% reduction in its regional rate using the 2023 rate book compared with the 2022 rate book. Contrast this with an average-risk beneficiary in Washington, D.C., that would receive an 11% increase in its regional rate in 2023 compared with 2022. Puerto Rico (–2%) and Maine (–1%) would see the smallest year-over-year change, while D.C. (11%), New York (7%), and California (6%) would see the largest increases.
In the case of Maine, a –1% regional trend for 2023 is most useful when you compare it to the national average for the same time period, which was +4%. This means an average beneficiary in Maine became 5% less expensive relative to an average beneficiary in the United States from 2022 to 2023 and the ACO faces a 5% headwind using the 2023 rate book. This is problematic when you consider that regional health care expenditures in 2020 and 2021 were likely influenced by state and local COVID-19 restrictions and cultural norms instead of by structural changes in the way care is delivered in these markets.
What are the implications?
The current REACH rate book will create arbitrary winners and losers based on vast regional variation in Medicare spending that was exacerbated by the pandemic. Some ACOs will see lower benchmarks in 2023 because of CMS’s including pandemic-stricken years. Let’s say, the Maine ACO sees a 2% decrease in its benchmark. This could make participation untenable when considering CMS keeps the first 3% of savings for itself. The Maine ACO would have to generate 5% in savings to collect any reward for its participation. ACOs in the model collectively generated 3.3% in savings in 2021, the only year for which data are available.
Additionally, decreased savings reduces the opportunity for ACOs to reinvest earned shared savings back into patient care through care coordinators, quality improvement efforts, enhanced health information technology, home visits, and other programs that help provider better care at lower costs.
Policy Considerations
CMS should consider approaches to mitigate the potential negative impacts, such as:
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More